Table 2.

Characteristics of patients with sudden (n = 4) or gradual onset (n = 19) of blastic transformation


Characteristics

SBT

Gradual BP
No. patients   4   19  
Best CG response, no. patients   
    CR   4   0  
    PR   0   2  
    Minor   0   2  
    CHR only   0   11  
    No CHR   0   8  
Best molecular response, no. patients   
    Undetectable   1   0* 
    < 0.05   1   0  
    ≥ 0.05   2   5  
Median time to best CG response, mo (range)   45 (3-6)   9.3 (3-22)  
Median time from diagnosis to imatinib, mo (range)   2.3 (0.1-34.9)   73.2 (0.9-171.5)  
Time from start of imatinib to BP, mo (range)   19.5 (12-25)   7.3 (1.9-54.3)  
Morphology, no. patients   
    Lymphoid   2   8  
    Myeloid   2   8  
    Unknown   0   3  
CE at start of imatinib, no. patients   0   5  
CE at BP, no. patients   4   3 
Prior therapy, no. patients   
    IFN-α   1   16  
    None   3   3  
Sokal risk group, no. patients low/intermediate/high   3/1/0   10/4/5  
No. dead
 
0
 
15
 

Characteristics

SBT

Gradual BP
No. patients   4   19  
Best CG response, no. patients   
    CR   4   0  
    PR   0   2  
    Minor   0   2  
    CHR only   0   11  
    No CHR   0   8  
Best molecular response, no. patients   
    Undetectable   1   0* 
    < 0.05   1   0  
    ≥ 0.05   2   5  
Median time to best CG response, mo (range)   45 (3-6)   9.3 (3-22)  
Median time from diagnosis to imatinib, mo (range)   2.3 (0.1-34.9)   73.2 (0.9-171.5)  
Time from start of imatinib to BP, mo (range)   19.5 (12-25)   7.3 (1.9-54.3)  
Morphology, no. patients   
    Lymphoid   2   8  
    Myeloid   2   8  
    Unknown   0   3  
CE at start of imatinib, no. patients   0   5  
CE at BP, no. patients   4   3 
Prior therapy, no. patients   
    IFN-α   1   16  
    None   3   3  
Sokal risk group, no. patients low/intermediate/high   3/1/0   10/4/5  
No. dead
 
0
 
15
 

BP indicates blast phase; CE, clonal evolution.

*

Only 5 patients were evaluable.

Of 10 evaluable patients.

or Create an Account

Close Modal
Close Modal